Albemarle — Feb 11, 2026 release

• Achieved approximately $450 million of cost and productivity improvements, exceeding the initial target of $300 to $400 million. • Closed sale of 50% stake in the Eurecat joint venture for $123 million cash in January 2026; on track to close sale of controlling stake in Ketjen in Q1 2026. • Introducing full-year 2026 outlook considerations, including ranges based on updated lithium market price scenarios: ◦ New scenarios highlight improved lithium market conditions and operational performance. ◦ Full-year 2026 capital expenditures expected to be approximately flat year-over-year, reflecting consistent sustaining capital, Ketjen divestiture and targeted growth capital focused on productivity gains and resource development. ◦ Meaningful free cash flow generation assuming recent higher lithium prices. (a)    See Non-GAAP Reconciliations for further details. (b)    Defined as Operating Cash Flow divided by Adj. EBITDA, which is a non-GAAP measure. See Non-GAAP Reconciliations for further details. "Our results for the fourth quarter and full year 2025 are a testament to our team’s focus on execution amid dynamic market conditions. Albemarle achieved year-over-year sales growth of more than 15% in the fourth quarter, as well as strong full-year cash flow generation and significant cost and productivity improvements,” said Kent Masters, Chairman and CEO. “The steps we have taken to optimize our asset portfolio, reduce costs and strengthen our financial flexibility have i